No longer an island: Japan’s drug pricing has global consequences

Unpredictable reimbursement cuts drive away research, investment and new medicines A drug store in Tokyo. Eli Lilly's CEO says Japan's current pricing system penalizes innovative medicines for their effectiveness, leaves patients with a limited range of treatments, and makes the country a less attractive destination for global investment. © AP David A. Ricks is chair and chief executive officer of Eli Lilly and Company.

Read the full article at the source →